inlexzo™
gemcitabine intravesical system | 225 mg

You are cordially invited to attend a live educational program:

INLEXZO™: An Innovative Intravesical Drug Releasing System

Presented by

David Yee, MD
Director of Urology and Genitourinary Oncology Services
Sutter Medcl Fndtn Uro, Roseville, CA

Speaker is a paid consultant of Johnson & Johnson

Data rates may apply.

Date

Wednesday, November 19, 2025
at 6:00 PM Pacific Time

Location

Stark's Steak and Seafood
521 Adams Street,
Santa Rosa, California 95401
(707) 546-5100

We look forward to your participation in this informative discussion. Reserve your spot now by contacting your Representative from Johnson & Johnson, Eddie Alcantar at ealcanta@its.jnj.com (530) 713-7339, or visit
https://janssenspeakerprograms.my.site.com/Registration/s?l=a12Vt000009HqZh

Learning Objectives

- **Overview of BCG-unresponsive NMIBC/CIS considerations**
- **Describe the mechanism of delivery of INLEXZO™**
- **Review the indication, efficacy, and safety profile of INLEXZO™**
- **Summarize INLEXZO™ dosing and administration**
- **Education on the INLEXZO™ insertion and removal procedure**
- **Access and office support for INLEXZO™**

INDICATION

INLEXZO™ (gemcitabine intravesical system) is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma *in situ* (CIS), with or without papillary tumors.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

INLEXZO™ is contraindicated in patients with:

- Perforation of the bladder.
- Prior hypersensitivity reactions to gemcitabine or any component of the product.

WARNINGS AND PRECAUTIONS

Risks in Patients with Perforated Bladder

INLEXZO™ may lead to systemic exposure to gemcitabine and to severe adverse reactions if administered to patients with a perforated bladder or to those in whom the integrity of the bladder mucosa has been compromised.

Evaluate the bladder before the intravesical administration of INLEXZO™ and do not administer to patients with a perforated bladder or mucosal compromise until bladder integrity has been restored.

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed.

If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials. Thank you for your cooperation.

This promotional educational activity is not accredited. The program content is developed by Johnson & Johnson. Speakers are paid consultants presenting on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.

The personal information you provide may be used to contact you about your request to attend the Janssen Biotech, Inc., educational program using your preferred method of communication as indicated by you. This information may be shared with Janssen Biotech, Inc., its affiliates, and a third party for the sole purpose of completing your registration for this program and as required by law.

Johnson&Johnson

Please see next page for additional Important Safety Information and read accompanying full Prescribing Information and Instructions for Use for INLEXZO™.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Risk of Metastatic Bladder Cancer with Delayed Cystectomy

Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. The risk of developing muscle invasive or metastatic bladder cancer increases the longer cystectomy is delayed in the presence of persisting CIS.

Of the 83 evaluable patients with BCG-unresponsive CIS treated with INLEXZO™ in Cohort 2 of SunRISe-1, 7 patients (8%) progressed to muscle invasive (T2 or greater) bladder cancer. Three patients (3.5%) had progression determined at the time of cystectomy. The median time between determination of persistent or recurrent CIS or T1 and progression to muscle invasive disease was 94 days.

Magnetic Resonance Imaging (MRI) Safety

INLEXZO™ can only be safely scanned with MRI under certain conditions. Refer to section 5.3 of the USPI for details on conditions.

Embryo-Fetal Toxicity

Based on animal data and its mechanism of action, INLEXZO™ can cause fetal harm when administered to a pregnant woman if systemic exposure occurs. In animal reproduction studies, systemic administration of gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits.

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after final removal of INLEXZO™. Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after final removal of INLEXZO™.

ADVERSE REACTIONS

Serious adverse reactions occurred in 24% of patients receiving INLEXZO™. Serious adverse reactions that occurred in >2% of patients included urinary tract infection, hematuria, pneumonia, and urinary tract pain. Fatal adverse reactions occurred in 1.2% of patients who received INLEXZO™, including cognitive disorder.

The most common (>15%) adverse reactions, including laboratory abnormalities, were urinary frequency, urinary tract infection, dysuria, micturition urgency, decreased hemoglobin, increased lipase, urinary tract pain, decreased lymphocytes, hematuria, increased creatinine, increased potassium, increased AST, decreased sodium, bladder irritation, and increased ALT.

USE IN SPECIFIC POPULATIONS

Pregnancy

There are no available data on the use of INLEXZO™ in pregnant women to inform a drug-associated risk.

Please see Embryo-Fetal Toxicity for risk information related to pregnancy.

Lactation

Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for 1 week after final removal of INLEXZO™.

Females and Males of Reproductive Potential

Pregnancy Testing – Verify pregnancy status in females of reproductive potential prior to initiating INLEXZO™.

Contraception – Please see Embryo-Fetal Toxicity for information regarding contraception.

Infertility (Males) – Based on animal studies, INLEXZO™ may impair fertility in males of reproductive potential. It is not known whether these effects on fertility are reversible.

Geriatric Use

Of the patients given INLEXZO™ monotherapy in Cohort 2 of SunRISe-1, 72% were 65 years of age or older and 34% were 75 years or older. There were insufficient numbers of patients <65 years of age to determine if these patients respond differently to patients 65 years of age and older.

Please read accompanying full Prescribing Information and Instructions for Use for INLEXZO™.

cp-520096v1

Johnson&Johnson

inlexzo™
gemcitabine intravesical system | 225 mg